P1451: PRELIMINARY RESULTS FROM THE FLU/CY/ALEMTUZUMAB ARM OF THE PHASE I BALLI-01 TRIAL OF UCART22, AN ANTI-CD22 ALLOGENEIC CAR-T CELL PRODUCT, IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) CD22+ B-CELL ALL
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2022-06-01
|
| Series: | HemaSphere |
| Online Access: | http://journals.lww.com/10.1097/01.HS9.0000848660.69944.40 |
| _version_ | 1797287222066544640 |
|---|---|
| author | N. Jain G. Roboz M. Konopleva H. Liu G. Schiller E. Jabbour P. Desai D. Whitfield A. Haider O. Zernovak M. Frattini C. Brownstein R. Larson |
| author_facet | N. Jain G. Roboz M. Konopleva H. Liu G. Schiller E. Jabbour P. Desai D. Whitfield A. Haider O. Zernovak M. Frattini C. Brownstein R. Larson |
| author_sort | N. Jain |
| collection | DOAJ |
| first_indexed | 2024-03-07T18:29:49Z |
| format | Article |
| id | doaj.art-400ed3fd79f54286bac6754e8300ce9c |
| institution | Directory Open Access Journal |
| issn | 2572-9241 |
| language | English |
| last_indexed | 2024-03-07T18:29:49Z |
| publishDate | 2022-06-01 |
| publisher | Wiley |
| record_format | Article |
| series | HemaSphere |
| spelling | doaj.art-400ed3fd79f54286bac6754e8300ce9c2024-03-02T06:40:31ZengWileyHemaSphere2572-92412022-06-0161333133410.1097/01.HS9.0000848660.69944.40202206003-01333P1451: PRELIMINARY RESULTS FROM THE FLU/CY/ALEMTUZUMAB ARM OF THE PHASE I BALLI-01 TRIAL OF UCART22, AN ANTI-CD22 ALLOGENEIC CAR-T CELL PRODUCT, IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) CD22+ B-CELL ALLN. Jain0G. Roboz1M. Konopleva2H. Liu3G. Schiller4E. Jabbour5P. Desai6D. Whitfield7A. Haider8O. Zernovak9M. Frattini10C. Brownstein11R. Larson121 Leukemia, The University of Texas MD Anderson Cancer Center, Houston2 Medicine, Weill Cornell Medicine/New York Presbyterian Hospital, New York1 Leukemia, The University of Texas MD Anderson Cancer Center, Houston3 Medicine, The University of Chicago, Chicago4 Medicine, David Geffen School of Medicine at UCLA, Los Angeles1 Leukemia, The University of Texas MD Anderson Cancer Center, Houston2 Medicine, Weill Cornell Medicine/New York Presbyterian Hospital, New York5 Cellectis, Inc., New York, United States of America5 Cellectis, Inc., New York, United States of America5 Cellectis, Inc., New York, United States of America5 Cellectis, Inc., New York, United States of America5 Cellectis, Inc., New York, United States of America3 Medicine, The University of Chicago, Chicagohttp://journals.lww.com/10.1097/01.HS9.0000848660.69944.40 |
| spellingShingle | N. Jain G. Roboz M. Konopleva H. Liu G. Schiller E. Jabbour P. Desai D. Whitfield A. Haider O. Zernovak M. Frattini C. Brownstein R. Larson P1451: PRELIMINARY RESULTS FROM THE FLU/CY/ALEMTUZUMAB ARM OF THE PHASE I BALLI-01 TRIAL OF UCART22, AN ANTI-CD22 ALLOGENEIC CAR-T CELL PRODUCT, IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) CD22+ B-CELL ALL HemaSphere |
| title | P1451: PRELIMINARY RESULTS FROM THE FLU/CY/ALEMTUZUMAB ARM OF THE PHASE I BALLI-01 TRIAL OF UCART22, AN ANTI-CD22 ALLOGENEIC CAR-T CELL PRODUCT, IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) CD22+ B-CELL ALL |
| title_full | P1451: PRELIMINARY RESULTS FROM THE FLU/CY/ALEMTUZUMAB ARM OF THE PHASE I BALLI-01 TRIAL OF UCART22, AN ANTI-CD22 ALLOGENEIC CAR-T CELL PRODUCT, IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) CD22+ B-CELL ALL |
| title_fullStr | P1451: PRELIMINARY RESULTS FROM THE FLU/CY/ALEMTUZUMAB ARM OF THE PHASE I BALLI-01 TRIAL OF UCART22, AN ANTI-CD22 ALLOGENEIC CAR-T CELL PRODUCT, IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) CD22+ B-CELL ALL |
| title_full_unstemmed | P1451: PRELIMINARY RESULTS FROM THE FLU/CY/ALEMTUZUMAB ARM OF THE PHASE I BALLI-01 TRIAL OF UCART22, AN ANTI-CD22 ALLOGENEIC CAR-T CELL PRODUCT, IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) CD22+ B-CELL ALL |
| title_short | P1451: PRELIMINARY RESULTS FROM THE FLU/CY/ALEMTUZUMAB ARM OF THE PHASE I BALLI-01 TRIAL OF UCART22, AN ANTI-CD22 ALLOGENEIC CAR-T CELL PRODUCT, IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) CD22+ B-CELL ALL |
| title_sort | p1451 preliminary results from the flu cy alemtuzumab arm of the phase i balli 01 trial of ucart22 an anti cd22 allogeneic car t cell product in patients with relapsed refractory r r cd22 b cell all |
| url | http://journals.lww.com/10.1097/01.HS9.0000848660.69944.40 |
| work_keys_str_mv | AT njain p1451preliminaryresultsfromtheflucyalemtuzumabarmofthephaseiballi01trialofucart22ananticd22allogeneiccartcellproductinpatientswithrelapsedrefractoryrrcd22bcellall AT groboz p1451preliminaryresultsfromtheflucyalemtuzumabarmofthephaseiballi01trialofucart22ananticd22allogeneiccartcellproductinpatientswithrelapsedrefractoryrrcd22bcellall AT mkonopleva p1451preliminaryresultsfromtheflucyalemtuzumabarmofthephaseiballi01trialofucart22ananticd22allogeneiccartcellproductinpatientswithrelapsedrefractoryrrcd22bcellall AT hliu p1451preliminaryresultsfromtheflucyalemtuzumabarmofthephaseiballi01trialofucart22ananticd22allogeneiccartcellproductinpatientswithrelapsedrefractoryrrcd22bcellall AT gschiller p1451preliminaryresultsfromtheflucyalemtuzumabarmofthephaseiballi01trialofucart22ananticd22allogeneiccartcellproductinpatientswithrelapsedrefractoryrrcd22bcellall AT ejabbour p1451preliminaryresultsfromtheflucyalemtuzumabarmofthephaseiballi01trialofucart22ananticd22allogeneiccartcellproductinpatientswithrelapsedrefractoryrrcd22bcellall AT pdesai p1451preliminaryresultsfromtheflucyalemtuzumabarmofthephaseiballi01trialofucart22ananticd22allogeneiccartcellproductinpatientswithrelapsedrefractoryrrcd22bcellall AT dwhitfield p1451preliminaryresultsfromtheflucyalemtuzumabarmofthephaseiballi01trialofucart22ananticd22allogeneiccartcellproductinpatientswithrelapsedrefractoryrrcd22bcellall AT ahaider p1451preliminaryresultsfromtheflucyalemtuzumabarmofthephaseiballi01trialofucart22ananticd22allogeneiccartcellproductinpatientswithrelapsedrefractoryrrcd22bcellall AT ozernovak p1451preliminaryresultsfromtheflucyalemtuzumabarmofthephaseiballi01trialofucart22ananticd22allogeneiccartcellproductinpatientswithrelapsedrefractoryrrcd22bcellall AT mfrattini p1451preliminaryresultsfromtheflucyalemtuzumabarmofthephaseiballi01trialofucart22ananticd22allogeneiccartcellproductinpatientswithrelapsedrefractoryrrcd22bcellall AT cbrownstein p1451preliminaryresultsfromtheflucyalemtuzumabarmofthephaseiballi01trialofucart22ananticd22allogeneiccartcellproductinpatientswithrelapsedrefractoryrrcd22bcellall AT rlarson p1451preliminaryresultsfromtheflucyalemtuzumabarmofthephaseiballi01trialofucart22ananticd22allogeneiccartcellproductinpatientswithrelapsedrefractoryrrcd22bcellall |